Thrombogenic Properties of Surface Factor; Evidence for an Anti-Surface Factor Activity in Canine Plasma.^[*]

Summary

Purified surface factor (SF or activation product) was prepared from canine plasma and its effect was studied on 22 dogs. It was shown that intravenous injection of SF increased the coagulability of the circulating blood (in vitro tests) and induced thrombosis in areas of vascular stasis (in vivo assay). The hypercoagulability was associated with the injected SF preparation and with no other known clotting factor increase. A second injection performed 61 minutes after the first was less effective. The survival period of injected SF seemed to be relatively short. This might be attributable, in part, to an inhibitory mechanism acting against SF (anti-SF) in plasma. Experimental evidence of the existence of such an inhibitor and its “progressive” mode of action is provided. Anti-SF has a variable titer normally, but appears to increase after the intravenous SF injection in dogs.

^* Aided by Grants HE-01510-10 and HE-06350-02 from the NIH Division of Research Grants and Fellowships, USPHS.

^** Present Address: Department of Medicine, Athena Clinic, Victoros Hugo 12, Athenai, Greece.

• References

• 1 Ratnoff O. D, Davie E. W, Mallett D. L. Studies on the action of Hageman factor: Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J. clin. Invest. 40: 803 1961;
• 2 Iatridis S. G, Wilson E. G, Ferguson J. H, Rierson H. A. Blood clotting activities of thrombolytic agents with special reference to a Hageman-like effect. Thrombos. Diathes. haemorrh. (Stuttg.) 5: 50 1960;
• 3 Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Lab. Invest. 11 (Suppl. 37) 1 1959;
• 4 Soldier J. P, Prou-Wartelle O. New data on Hageman factor and plasma thromboplastin antecedent: The role of “contact” in the initial phase of blood coagulation. Brit. J. Haemat. 6: 88 1960;
• 5 Iatridis S. G, Ferguson J. H. Effect of physical exercise on blood clotting and fibrinolysis. J. appi. Physiol. 18: 337 1963;
• 6 Wessler S. Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis. J. clin. Invest. 34: 647 1955;
• 7 Wessler S, Reimer S. M. The role of human coagulation factors in serum induced thrombosis. J. clin Invest. 39: 262 1960;
• 8 Wessler S. Thrombosis in the presence of vascular stasis. Amer. J. Med. 33: 648 1962;
• 9 Henderson E. S, Rapaport S. I. The thrombotic activity of activation product. J. clin. Invest. 41: 235 1962;
• 10 Didisheim P, Vandervoort R. L. E, Rytting J. E. Formation of serum thrombotic accelerator (STA) in plasma. Clin. Res. 10: 77 1962;
• 11 Iatridis S. G, Ferguson J. H, Iatridis P. G. Thrombotic and antisurface factor activity in dog blood. Fed. Proc. 22: 620 1963;
• 12 Iatridis S. G, Iatridis P. G, Ferguson J. H. Thrombotic and surface factor studies in rabbits. Physiologist 6: 207 1963;
• 13 Iatridis S. G, Ferguson J. H. Active Hageman factor: A plasma lysokinase of the human fibrinolytic system. J. clin. Invest. 41: 1277 1962;
• 14 Mertz E. T, Owen G. A. Imidazole buffer: its use in blood clotting studies. Proc. Soc. exp. Biol. 43: 204 1940;
• 15 Quick A. J, Stanley-Brown M, Bancroft F. W. A study of the coagulation defect in hemophilia and in jaundice. Amer. J. med. Sci. 190: 501 1935;
• 16 Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests. A presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J. lab. clin. Med. 41: 637 1953;
• 17 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature (Lond.) 174: 880 1954;
• 18 Ratnoff O. D, Menzie G. I. A new method for the determination of fibrinogen in small samples of plasma. J. Lab. clin. Med. 37: 316 1951;
• 19 Hjort P, Rapaport S. I, Owren P. A. A simple specific one-stage prothrombin assay using Russell’s viper venom in cephalin suspension. J. Lab. clin. Med. 46: 89 1955;
• 20 Biggs R, Macfariane R. G. Human blood coagulation and its disorders. Oxford: Blackwell Scientific Publications; 2nd edit.. 406 1957
• 21 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 3: 201 1951;
• 22 Poll J. G, Robinson J. Assay of plasma antihemophilic globulin (AHG). Brit. J. Haemat. 5: 17 1959;
• 23 Iatridis S. G, Ferguson J. H. A two-stage assay method for Hageman factor activity. Thrombos. Diathes. haemorrh. (Stuttg.) 8: 46 1962;
• 24 Hellem A. J. The adhesiveness of human blood platelets in vitro. Scand. J. clin. Lab. Invest. 12 (Suppl. 51) 1 1960;
• 25 Nygaard K. K. A direct method of counting platelets in oxalated plasma. Proc. Mayo Clin. 8: 365 1933;
• 26 DeN icola P, Mazzetti G. M. Evaluation of thrombelastography. Amer. J. clin. Path. 25: 447 1955;